Search | IOVS | ARVO Journals

Showing 1 – 20 of 175

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2025

Early insights on the real-world use of aflibercept 8 mg among treatment-naive eyes with diabetic macular edema

Nitish Mehta; Steven Sherman; Keran Moll; Dana Murdock; Nick Boucher; Rishi P Singh; Ferhina S. Ali; Durga Borkar; Theodore Leng; Michael Javaheri

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):2398.

ARVO Annual Meeting Abstract June 2025

Early insights from real-world use of aflibercept 8 mg among eyes with diabetic macular edema (DME) switching from other anti-VEGF agents

Michael Javaheri; Steven Sherman; Keran Moll; Dana Murdock; Nick Boucher; Rishi P Singh; Ferhina S. Ali; Durga Borkar; Theodore Leng; Nitish Mehta

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):2396.

ARVO Annual Meeting Abstract June 2025

Economic benefit of aflibercept 8 mg versus faricimab in the treatment of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in the United States

Andreas Kuznik; Steven Sherman; Nimesh Patel

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):1909.

ARVO Annual Meeting Abstract June 2025

Early insights from real-world use of aflibercept 8 mg among eyes with neovascular age-related macular degeneration (nAMD) switching from other anti-VEGF agents

Theodore Leng; Steven Sherman; Dana Murdock; Keran Moll; Nick Boucher; Nitish Mehta; Michael Javaheri; Durga Borkar; Rishi P Singh; Ferhina S. Ali

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):3110.

ARVO Annual Meeting Abstract June 2025

Early real-world use of aflibercept 8 mg in treatment-naive patients with neovascular age-related macular degeneration

Ferhina S. Ali; Steven Sherman; Dana Murdock; Keran Moll; Nick Boucher; Nitish Mehta; Michael Javaheri; Durga Borkar; Theodore Leng; Rishi P Singh

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):3095.

ARVO Annual Meeting Abstract June 2025

Lower socioeconomic status is associated with increased bevacizumab use among patients initiating anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME)

Judy E Kim; Keran Moll; Dana Murdock; Steven Sherman

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):4017.

ARVO Annual Meeting Abstract June 2025

Depletion of Retinal Antigen Presenting Cells Does Not Limit the Development of Spontaneous Autoimmune Uveoretinitis

Scott W McPherson; Joe Sherman; Laura Burgstaler; Abigail Patin; Heidi Roehrich; Dale Gregerson

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):6138.

ARVO Annual Meeting Abstract June 2024

Evaluating Post-operative Flare in Glaucoma Surgery: Miniject, Microshunt, Baerveldt Tube, Cataract & ECP and Trabeculectomy

Ananth Ranjit; Bhavin Patel; Thomas Edward James Sherman; Andrew Swampillai; Elizabeth Galvis; K Sheng Lim; ANDREW AMON

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3522.

ARVO Annual Meeting Abstract June 2024

Evaluating Tonographic Outflow Facility, Efficacy & Safety of Miniject Implant For Glaucoma

Bhavin Patel; Ananth Ranjit; Andrew Swampillai; Thomas Edward James Sherman; K Sheng Lim

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3488.

ARVO Annual Meeting Abstract June 2024

Pharmacodynamic efficacy of second-generation intravitreal axitinib implant (Axpaxli™) in a VEGF challenge rabbit model

Charles Blizzard; Chintan Patel; MADHOOSUDAN PATIL; Erica Kahn; Joe Iacona; Daniel Domingues; Alyssa Whalen; Olivia Sherman; Mark Ransbottom; Dinesh Haswani; Rabia Gurses Ozden; Peter Jarrett

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6520.

ARVO Annual Meeting Abstract June 2024

Optimized pharmacokinetic profile of intravitreal axitinib intravitreal implant (Axpaxli™): a comparison of first- and second-generation implants

MADHOOSUDAN PATIL; Chintan Patel; Erica Kahn; Joe Iacona; Daniel Domingues; Alyssa Whalen; Charles Blizzard; Olivia Sherman; Mark Ransbottom; Dinesh Haswani; Rabia Gurses Ozden; Peter Jarrett

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1937.

ARVO Annual Meeting Abstract June 2024

Long-term safety of repeated intravitreal axitinib implant (Axpaxli™) administrations in non-human primates

Chintan Patel; MADHOOSUDAN PATIL; Erica Kahn; Joe Iacona; Daniel Domingues; Alyssa Whalen; Charles Blizzard; Olivia Sherman; Mark Ransbottom; Dinesh Haswani; Rabia Gurses Ozden; Peter Jarrett

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1936.

ARVO Annual Meeting Abstract June 2024

Longitudinal characterization of retinal degeneration in a nonhuman primate model of Batten disease.

Lauren Renner; Jonathan Stoddard; Hannah Woolard; Rachel Spears; Rene Reynaga; Alison Weiss; Lawrence Sherman; Jodi McBride; Trevor J Mcgill; Martha Neuringer

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1510.

ARVO Annual Meeting Abstract June 2024

Spontaneous Autoimmune Uveoretinitis Is Enhanced by Activation of Retinal Antigen Presenting Cells

Scott W McPherson; Heidi Roehrich; Yunan Li; Joe Sherman; Laura Burgstaler; Dale S. Gregerson

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5072.

Research Opportunities November 2023

Report From the 2022 Mary Tyler Moore Vision Initiative Diabetic Retinal Disease Clinical Endpoints Workshop

PDF

S. Robert Levine; Martin G. Myers; Ryan Barunas; Dolly S. Chang; Sanjoy Dutta; Ted Maddess; Jeffrey M. Liebmann; Steve Sherman; Melvina Eydelman; Jennifer K. Sun; Wiley Chambers; Kerstin Wickström; Ulrich F. O. Luhmann; Martin Pallinat; Adam Glassman; Lloyd Paul Aiello; Dorene S. Markel; Thomas W. Gardner
TAGS: diabetes mellitus, retinal diseases, surrogate endpoints, vision
Trans. Vis. Sci. Tech.. 2023; 12(11):33. https://doi.org/10.1167/tvst.12.11.33

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2023

Characterization of late proliferative zone in developing human retina

Kiara Eldred; Isabel Ortuño; Juliette Wohlschlegel; Sidnee Petter; Dawn Hoffer; Stephanie Sherman; Ian Glass; Thomas A Reh

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2833.

ARVO Annual Meeting Abstract June 2023

Maintenance of CNTF secreting vector in genetically engineered ARPE-19 cells over clinical cell scale up

Sid Plakkot; Matthew Fera; Arne Nystuen; Crystal Cortellessa; Sandy Sherman; Konrad Kauper

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3662.

ARVO Annual Meeting Abstract June 2023

Impact of initial monthly doses of aflibercept on visual outcomes in eyes with diabetic macular edema in routine clinical practice in the US

Nitish Mehta; Ferhina S. Ali; Rishi Singh; Nick Boucher; Fabiana Q. Silva; Rutvi Desai; Steven Sherman

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3646.

ARVO Annual Meeting Abstract June 2023

The Relationship between Unstable Housing, Food Insecurity and Vision Status in the Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine (MI-SIGHT) Program

Mikaelah Aron Johnson-Griggs; Eric Sherman; Patrice Marie Hicks; Ming-Chen Lu; Leslie M. Niziol; Angela Elam; Maria A. Woodward; Amanda Bicket; Sarah Wood; Denise John; Leroy Johnson; Martha Kershaw; Jason Zhang; David C Musch; Paula Anne Newman-Casey

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2479.

ARVO Annual Meeting Abstract June 2023

Changes in intraocular pressure and tonographic outflow facility following combined viscocanaloplasty and trabeculotomy with the OMNI surgical system.

Thomas Sherman; Andrew Swampillai; Saurabh Goyal; Elizabeth Galvis; Andrew Amon; Angela Yoganathan; Kin Sheng Lim

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3480.

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Early insights on the real-world use of aflibercept 8 mg among treatment-naive eyes with diabetic macular edema

Early insights from real-world use of aflibercept 8 mg among eyes with diabetic macular edema (DME) switching from other anti-VEGF agents

Economic benefit of aflibercept 8 mg versus faricimab in the treatment of patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) in the United States

Early insights from real-world use of aflibercept 8 mg among eyes with neovascular age-related macular degeneration (nAMD) switching from other anti-VEGF agents

Early real-world use of aflibercept 8 mg in treatment-naive patients with neovascular age-related macular degeneration

Lower socioeconomic status is associated with increased bevacizumab use among patients initiating anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME)

Depletion of Retinal Antigen Presenting Cells Does Not Limit the Development of Spontaneous Autoimmune Uveoretinitis

Evaluating Post-operative Flare in Glaucoma Surgery: Miniject, Microshunt, Baerveldt Tube, Cataract & ECP and Trabeculectomy

Evaluating Tonographic Outflow Facility, Efficacy & Safety of Miniject Implant For Glaucoma

Pharmacodynamic efficacy of second-generation intravitreal axitinib implant (Axpaxli™) in a VEGF challenge rabbit model

Optimized pharmacokinetic profile of intravitreal axitinib intravitreal implant (Axpaxli™): a comparison of first- and second-generation implants

Long-term safety of repeated intravitreal axitinib implant (Axpaxli™) administrations in non-human primates

Longitudinal characterization of retinal degeneration in a nonhuman primate model of Batten disease.

Spontaneous Autoimmune Uveoretinitis Is Enhanced by Activation of Retinal Antigen Presenting Cells

Report From the 2022 Mary Tyler Moore Vision Initiative Diabetic Retinal Disease Clinical Endpoints Workshop

Characterization of late proliferative zone in developing human retina

Maintenance of CNTF secreting vector in genetically engineered ARPE-19 cells over clinical cell scale up

Impact of initial monthly doses of aflibercept on visual outcomes in eyes with diabetic macular edema in routine clinical practice in the US

The Relationship between Unstable Housing, Food Insecurity and Vision Status in the Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine (MI-SIGHT) Program

Changes in intraocular pressure and tonographic outflow facility following combined viscocanaloplasty and trabeculotomy with the OMNI surgical system.

To View More...

You must be signed into an individual account to use this feature.